The verbal presentations are scheduled as follows:
SESSION I / Monday, May 23 / 8 a.m. - 8:30 p.m.
Re-Hospitalization Rates of Acute Coronary Syndrome Patients in Real World Clinical Practice: Observations from a National Administrative Claims Data
Tunceli O1, Gandhi SK2, Bhandary D2, Stephenson JJ1, Gold A2, Fu AC1, Kern DM1, Singer J1 1HealthCore, Inc., Wilmington, Del.; 2AstraZeneca Pharmaceuticals LP, Wilmington, Del.
SESSION II / Tuesday, May 24 / 8 a.m. - 7:45 p.m.
Trends of Hepatitis A Incidence from 2005 to 2008
Eisenberg D1, Changolkar AK2, Misurski DA2 1HealthCore, Inc., Wilmington, Del.; 2GlaxoSmithKline, Philadelphia, Pa.
Concomitant Asthma Medication Use in Patients Using Omalizumab: Results from Three Large Insurance Claims Databases
Lafeuille MH1, Duh MS2, Zhang J3, Wertz D4, Gu T4, Tang J2, Lefebvre P1
1Groupe d'analyse, Lte, Montreal, Canada; 2Analysis Group, Inc., Boston, Mass; 3Novartis Pharmaceuticals Corporation, East Hanover, N.J/; 4HealthCore, Inc., Wilmington, Del.
SESSION III / Wednesday, May 25 / 8 a.m. 3 p.m.
Racial Disparities in African-American Versus White Women with Newly Diagnosed Breast Cancer in a Southeast United States Health Plan
Fisher M1, Cai Q1, Paoli CJ2, Lyons A3, Wasser T1, Rodriguez N4, White S5, Kallich J3, Barron J1, Brawley OW6
1HealthCore, Inc., Wilmington, Del.,; 2University of California, San Francisco, San Francisco, Calif.; 3Amgen, Inc., Thousand Oaks, Calif.; 4Blue Cross Blue Shield of Georgia, Atlanta, Ga., 5WellPoint, Atlanta, Ga; 6American Cancer Society, Atlanta, Ga.
Predictors of Proton Pump Inhibitor (PPI) Dosing Regimen Among Patients with Gastroesophageal Reflux Disease (GERD)
Eisenberg D1, Mody R2, Singer J1, Kamat SA1, Gerson LB3
1HealthCore, Inc., Wilmington, Del; 2Takeda Pharmaceuticals International, Inc., D
|Contact: Lori McLaughlin|